The haemodynamic effects of subcutaneous sumatriptan, a 5HT(1)-receptor agonist

被引:18
|
作者
Hood, S
Birnie, D
Hillis, S
机构
[1] UNIV GLASGOW, WESTERN INFIRM, DEPT MED & THERAPEUT, GLASGOW G11 6NT, LANARK, SCOTLAND
[2] UNIV GLASGOW, WESTERN INFIRM, DEPT CARDIOL, GLASGOW G11 6NT, LANARK, SCOTLAND
关键词
sumatriptan; 5-hydroxytryptamine; vasoconstriction; haemodynamics;
D O I
10.1111/j.1365-2125.1997.00555.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Previous in vivo studies with sumatriptan, a 5HT(1)-receptor agonist, have demonstrated vasopressor responses in the pulmonary and systemic arterial circulation. Pulmonary artery wedge pressure (PAWP) also increases after sumatriptan injection, raising the possibility of an additional venoconstrictive action or a negative inotropic effect. The mechanism for the rise in PAWP was investigated in the study. Methods Ten patients undergoing diagnostic coronary arteriography underwent haemodynamic monitoring. Results There was a significant rise (P<0.05) in systemic and pulmonary arterial pressure and total systemic and pulmonary vascular resistance. There was a similar rise (P<0.05) in PAWP and left ventricular end diastolic pressure (LVEDP). There was no change in cardiac output nor in peak rate of left ventricular pressure rise (dP/dt). Conclusions The sumatriptan induced rise in PAWP and LVEDP appears consequent upon increased afterload although a negative inotropic effect cannot be excluded.
引用
收藏
页码:327 / 328
页数:2
相关论文
共 50 条
  • [41] Hypothermic Effect of 5-HT1A Receptor Agonist: Comparison of Intranasal, Intraperitoneal, and Subcutaneous Routes of Administration
    N. K. Popova
    M. A. Tibeikina
    T. G. Amstislavskaya
    Bulletin of Experimental Biology and Medicine, 2008, 146 : 433 - 435
  • [42] Hypothermic Effect of 5-HT1A Receptor Agonist: Comparison of Intranasal, Intraperitoneal, and Subcutaneous Routes of Administration
    Popova, N. K.
    Tibeikina, M. A.
    Amstislavskaya, T. G.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2008, 146 (04) : 433 - 435
  • [43] COMBINED TREATMENT WITH A 5HT(1A) RECEPTOR AGONIST AND A MUSCARINIC ACETYLCHOLINE-RECEPTOR ANTAGONIST DISRUPTS WATER MAZE NAVIGATION BEHAVIOR
    RIEKKINEN, M
    SIRVIO, J
    TOIVANEN, T
    RIEKKINEN, P
    PSYCHOPHARMACOLOGY, 1995, 122 (02) : 137 - 146
  • [44] Comparison of the cardiovascular effects of the novel 5-HT1B/1D receptor agonist, SB 209509 (VML251), and sumatriptan in dogs
    Parsons, AA
    Parker, SG
    Raval, P
    Campbell, CA
    Lewis, VA
    Griffiths, R
    Hunter, AJ
    Hamilton, TC
    King, FD
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 30 (01) : 136 - 141
  • [45] 5HT AND 5HT2 RECOGNITION SITES ARE PRESENT IN THE 5HT RECEPTOR COMPLEX OF NCB-20 CELL-LINE
    NAKAKI, T
    ROTH, BL
    CHUANG, DM
    COSTA, E
    FEDERATION PROCEEDINGS, 1984, 43 (04) : 1092 - 1092
  • [46] 5HT(1A) RECEPTOR GENE AND BIPOLAR AFFECTIVE-DISORDER
    GUTIERREZ, B
    ARRANZ, M
    FANANAS, L
    VALLES, V
    GUILLAMAT, R
    VANOS, J
    COLLIER, D
    LANCET, 1995, 346 (8980): : 969 - 969
  • [47] The effects of the 5-HT6 receptor agonist EMD and the 5-HT7 receptor agonist AS19 on memory formation
    Meneses, A.
    Perez-Garcia, G.
    Liy-Salmeron, G.
    Flores-Galvez, D.
    Castillo, C.
    Castillo, E.
    BEHAVIOURAL BRAIN RESEARCH, 2008, 195 (01) : 112 - 119
  • [48] [H-3] SUMATRIPTAN LABELS BOTH 5-HT1D AND 5HT(1F) RECEPTOR-BINDING SITES IN THE GUINEA-PIG BRAIN - AN AUTORADIOGRAPHIC STUDY
    WAEBER, C
    MOSKOWITZ, MA
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1995, 352 (03) : 263 - 275
  • [49] GEPIRONE, A SELECTIVE SEROTONIN (5HT(1A)) PARTIAL AGONIST IN THE TREATMENT OF MAJOR DEPRESSION
    AMSTERDAM, JD
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1992, 16 (03): : 271 - 280
  • [50] 5HT(1) receptor activation inhibits exocrine pancreatic function in man
    Coulie, B
    Tack, J
    Maes, B
    Ghoos, Y
    Demedts, I
    Janssens, J
    GASTROENTEROLOGY, 1996, 110 (04) : A384 - A384